# Fotemustine in Treating Patients With Metastatic Melanoma

> **NCT00560118** · PHASE2 · TERMINATED · sponsor: **Institut du Cancer de Montpellier - Val d'Aurelle** · enrollment: 12 (actual)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **DRUG:** fotemustine

## Key facts

- **NCT ID:** NCT00560118
- **Lead sponsor:** Institut du Cancer de Montpellier - Val d'Aurelle
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-08-08
- **Primary completion:** 2008-08-31
- **Final completion:** 2008-08-31
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** In view of the slowness of the inclusions and the difficulty of carrying out the study, it was decided to put an end to this study.
- **Last updated:** 2025-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00560118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00560118, "Fotemustine in Treating Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00560118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*